Fundraising Fox
Lapix Therapeutics
Boston, US · Founded 2019 · Delaware corporation
Find your way into Lapix Therapeutics
Sign up to see every warm intro you have to Lapix Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lapix Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
LAPIX Therapeutics is a clinical-stage biopharmaceutical company developing an orally administered, non-immunosuppressive T-cell engager therapy for people with autoimmune diseases. Its lead therapeutic, LPX-TI641, is an antigen-agnostic TIM pathway agonist targeting TIM-3 and TIM-4 receptors to restore immune balance across a range of autoimmune conditions.
Founders & leadership
AF
Anas FathallahCo-Founder and CEOAnas Fathallah is Co-Founder and CEO of LAPIX Therapeutics, a clinical-stage biopharmaceutical company developing orally administered T-cell engager therapies for autoimmune diseases. He has background experience as a drug developer and clinical pharmacologist with a track record of advancing programs from early discovery into clinical development.
AF
Anas Fathallah, Ph.D.Chief Executive Officer and Co-Founder
Board
AG
Anthony GibneyBoard director
HM
Henry McKinnellBoard director
FL
Reported raises · per SEC filings
Form D private placements$14.9M disclosed across 4 rounds · 2022–2025
▶$2.2MraisedAug 2025 · 10 investors · Other TechnologyRule 506(b)
▶$2.2MraisedAug 2025 · 10 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Anas FathallahExecutive Officer, Director
- Anthony GibneyDirector
- Jason NorrisExecutive Officer, Director
- Francisco LeonDirector
- Henry McKinnellDirector
- Offering amount
- $5M
- Amount sold
- $2.2M
- Minimum investment
- $1K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedFeb 2025 · 25 investors · BiotechnologyRule 506(b)
▶$5.5MraisedFeb 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Henry McKinnellDirector
- Anthony GibneyDirector
- Anas FathallahExecutive Officer, Director
- Jason NorrisExecutive Officer, Director
- Francisco LeonDirector
- Offering amount
- $6M
- Amount sold
- $5.5M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.9MraisedApr 2023 · 32 investors · BiotechnologyRule 506(b)
▶$5.9MraisedApr 2023 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason NorrisDirector
- Anas FathallahExecutive Officer, Director
- Offering amount
- $14.6M
- Amount sold
- $5.9M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.2MraisedOct 2022 · 7 investors · Other TechnologyRule 506(b)
▶$1.2MraisedOct 2022 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Anas FathallahExecutive Officer, Director
- Jason NorrisExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.2M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Lapix Therapeutics.
Frequently asked questions
- What does Lapix Therapeutics do?
- LAPIX Therapeutics is a clinical-stage biopharmaceutical company developing an orally administered, non-immunosuppressive T-cell engager therapy for people with autoimmune diseases. Its lead therapeutic, LPX-TI641, is an antigen-agnostic TIM pathway agonist targeting TIM-3 and TIM-4 receptors to restore immune balance across a range of autoimmune conditions.
- How much funding has Lapix Therapeutics raised?
- Lapix Therapeutics has disclosed $14.9M raised across 4 rounds.
- Where is Lapix Therapeutics headquartered?
- Lapix Therapeutics is headquartered in Boston, US.